CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?

Capricor Therapeutics (CAPR) has surged 144% over the past month after phase III HOPE-3 trial data showed deramiocel, its cell therapy for Duchenne muscular dystrophy, reduced upper-limb function decline by 54%. The rally signals renewed investor confidence following a setback earlier this year when the FDA rejected the company's initial submission.

CAPR refined its regulatory strategy, narrowing the indication to focus specifically on upper-limb function preservation rather than a broader approval. The FDA accepted the resubmission and assigned a PDUFA target action date of November 22, 2026, giving the agency a two-year review window.

The 144% one-month gain reflects optimism around deramiocel's clinical profile in a rare disease with limited treatment options, though the extended timeline and regulatory risk remain substantial. The 54% reduction in functional decline represents a clinically meaningful endpoint in a progressive neuromuscular disorder where upper-limb mobility is critical for patient independence.